MASH awareness survey completed: no treatment, just insights
NCT ID NCT07201831
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study used online questionnaires to understand how well healthcare providers and people with or at risk for MASH (a liver disease) understand the links between MASH and heart, kidney, and metabolic conditions. About 1,330 participants completed the 25-minute survey. The goal was to gather information for future research, not to test any treatment.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Participants
-
1,330 people
The number who actually took part.
- Started
-
Oct 2025
- Finished
-
Jan 2026
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
Who is studied
The study population includes two population segments. The first segment is made up of Health Care Practitioners (HCPs) who self-report to being at least somewhat familiar with Metabolic dysfunction-associated steatohepatitis (MASH). The second segment consists of three subsegments defined as people who have been diagnosed with MASH, or people who have been diagnosed with Metabolic Associated Steatotic Liver Disease (MASLD), or people who have been identified as being at risk for developing MASH
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: HCP inclusion criteria * Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male or female, age above or equal to 18 years at the time of signing informed consent. * Licensed to practice medicine in one of the countries of interest: United States, Canada, France, Germany, Japan * Must be a practicing endocrinologist, hepatologist, cardiologist, obesity specialist, primary care physician, radiologist, nurse practitioner or physician assistant (NP/PA US only) * Must be at least "somewhat familiar" (as opposed to "not at all familiar) with Metabolic dysfunction-associated steatohepatitis (MASH) (do not need to be currently treating people with MASH) 6. Must have at least 2 years in practice 7. Must spend at least 50 percentage of their time in patient care Diagnosed patient inclusion criteria * Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male or female, age above or equal to 18 years at the time of signing informed consent. * Diagnosis of MASH or Metabolic Associated Steatotic Liver Disease (MASLD) within past 24 months * Live in one of the countries of interest: United States, Canada, France, Germany, Japan * Have at least one comorbid condition: obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease At risk patient inclusion criteria * Informed consent obtained before any study-related activities (study-related activities are any procedure related to recording of data according to the protocol). * Male or female, age above or equal to 18 years at the time of signing informed consent. * Live in one of the countries of interest: United States, Canada, France, Germany, Japan * Must have one or more risk factors associated with MASH \[obesity, pre-diabetes, type 2 diabetes (T2D), metabolic syndrome, dyslipidaemia, hypertension, cardiovascular disease, chronic kidney disease\], be diagnosed with steatosis (incidental finding) or have a blood test that shows raised liver enzymes. Exclusion Criteria: * Previous participation in this study. Participation is defined as having given informed consent in this study * Mental incapacity, unwillingness or language barriers precluding adequate understanding or cooperation
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Metabolic dysfunction associated steatohepatitis (MASH) are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Novo Nordisk Investigational Site
Plainsboro, New Jersey, 08536, United States
-
Novo Nordisk Investigational Site
Mississauga, Canada
-
Novo Nordisk Investigational Site
Puteaux, France
-
Novo Nordisk Investigational Site
Mainz, Germany
-
Novo Nordisk Investigational Site
Tokyo, Japan
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Underactive thyroid may worsen liver scarring in fatty liver disease
- Can cold exposure melt away liver fat?
- Can exercise melt away liver fat?
- A blood test for liver trouble may flag hidden risk in sleep apnea patients
- Can a weekly shot reverse liver damage from fatty liver disease?
- Thyroid trouble may worsen liver scarring in fatty liver disease